TD Asset Management Inc. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 83,146 shares of the company’s stock after buying an additional 7,651 shares during the quarter. TD Asset Management Inc.’s holdings in IDEXX Laboratories were worth $18,591,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. LS Investment Advisors LLC boosted its position in IDEXX Laboratories by 1.3% during the first quarter. LS Investment Advisors LLC now owns 3,424 shares of the company’s stock valued at $766,000 after purchasing an additional 45 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in IDEXX Laboratories by 4.7% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,192 shares of the company’s stock valued at $222,000 after purchasing an additional 54 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 3,131 shares of the company’s stock valued at $583,000 after buying an additional 56 shares during the last quarter. Security Asset Management lifted its position in shares of IDEXX Laboratories by 0.4% in the fourth quarter. Security Asset Management now owns 15,245 shares of the company’s stock valued at $2,836,000 after buying an additional 60 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its position in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 3,795 shares of the company’s stock valued at $706,000 after buying an additional 66 shares during the last quarter. Institutional investors and hedge funds own 88.58% of the company’s stock.

A number of research firms have recently issued reports on IDXX. Canaccord Genuity cut their price objective on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, April 3rd. Guggenheim began coverage on IDEXX Laboratories in a research report on Thursday. They issued a “buy” rating and a $276.00 price objective for the company. Finally, BidaskClub raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday, April 30th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $256.71.

IDXX opened at $256.11 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $176.11 and a 12-month high of $258.42. The company has a market capitalization of $22.04 billion, a PE ratio of 60.12 and a beta of 0.97. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The company had revenue of $576.06 million during the quarter, compared to analysts’ expectations of $575.04 million. During the same period last year, the firm posted $1.01 earnings per share. The business’s revenue was up 7.1% on a year-over-year basis. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current fiscal year.

In related news, Director Rebecca M. Henderson sold 8,790 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $241.57, for a total transaction of $2,123,400.30. Following the completion of the sale, the director now directly owns 27,486 shares of the company’s stock, valued at approximately $6,639,793.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Jonathan W. Ayers sold 28,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $249.02, for a total value of $6,972,560.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,150 shares of company stock valued at $12,754,596. 2.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/td-asset-management-inc-boosts-position-in-idexx-laboratories-inc-idxx/3022049.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: Buyback For Investors Defined

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.